Evidence map›Paper›PMID 31849931›Full record

ArticleFrontiers in immunology2019

Delineating Human B Cell Precursor Development With Genetically Identified PID Cases as a Model.

Marjolein W J Wentink, Tomas Kalina, Martin Perez-Andres, Lucia Del Pino Molina, Hanna IJspeert, François G Kavelaars, Arjan C Lankester, Quentin Lecrevisse, Jacques J M van Dongen, Alberto Orfao and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Inherited human TFIIIA deficiency disrupts T cell development.medRxiv : the preprint server for health sciences · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. NF-kB's contribution to B cell fate decisions.Frontiers in immunology · 2023
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Marjolein W J WentinkDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Tomas KalinaDepartment of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia.
Martin Perez-AndresDepartment of Medicine-Service Cytometry, Cancer Research Center (IBMCC-CSIC/USAL) and University of Salamanca, Salamanca, Spain.
Lucia Del Pino MolinaDepartment of Clinical Immunology, La Paz University Hospital, Lymphocyte Pathophysiology in Immunodeficiencies Group La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Hanna IJspeertDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
François G KavelaarsDepartment of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Arjan C LankesterDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.
Quentin LecrevisseDepartment of Medicine-Service Cytometry, Cancer Research Center (IBMCC-CSIC/USAL) and University of Salamanca, Salamanca, Spain.
Jacques J M van DongenDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.
Alberto OrfaoDepartment of Medicine-Service Cytometry, Cancer Research Center (IBMCC-CSIC/USAL) and University of Salamanca, Salamanca, Spain.
Mirjam van der BurgDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Erasmus MC · NLCentro de Investigación del Cáncer · ESLeiden University Medical Center · NLHospital La Paz Institute for Health Research · ESUniversity Hospital in Motol · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B-cell precursors (BCP) arise from hematopoietic stem cells in bone marrow (BM). Identification and characterization of the different BCP subsets has contributed to the understanding of normal B-cell development. BCP first rearrange their immunoglobulin (Ig) heavy chain (IGH) genes to form the pre-B-cell receptor (pre-BCR) complex together with surrogate light chains. Appropriate signaling via this pre-BCR complex is followed by rearrangement of the Ig light chain genes, resulting in the formation, and selection of functional BCR molecules. Consecutive production, expression, and functional selection of the pre-BCR and BCR complexes guide the BCP differentiation process that coincides with corresponding immunophenotypic changes. We studied BCP differentiation in human BM samples from healthy controls and patients with a known genetic defect in V(D)J recombination or pre-BCR signaling to unravel normal immunophenotypic changes and to determine the effect of differentiation blocks caused by the specific genetic defects. Accordingly, we designed a 10-color antibody panel to study human BCP development in BM by flow cytometry, which allows identification of classical preB-I, preB-II, and mature B-cells as defined via BCR-related markers with further characterization by additional markers. We observed heterogeneous phenotypes associated with more than one B-cell maturation pathway, particularly for the preB-I and preB-II stages in which V(D)J recombination takes place, with asynchronous marker expression patterns. Next Generation Sequencing of complete IGH gene rearrangements in sorted BCP subsets unraveled their rearrangement status, indicating that BCP differentiation does not follow a single linear pathway. In conclusion, B-cell development in human BM is not a linear process, but a rather complex network of parallel pathways dictated by V(D)J-recombination-driven checkpoints and pre-BCR/BCR mediated-signaling occurring during B-cell production and selection. It can also be described as asynchronous, because precursor B-cells do not differentiate as full population between the different stages, but rather transit as a continuum, which seems influenced (in part) by V-D-J recombination-driven checkpoints.

Indexed as

Cell DifferentiationChildFemaleFlow CytometryHumansImmunoglobulin Heavy ChainsImmunologic Deficiency SyndromesMalePrecursor Cells, B-LymphoidReceptors, Antigen, B-CellV(D)J RecombinationImmunoglobulin Heavy ChainsReceptors, Antigen, B-Cellbone marrowflow cytometryimmunoglobulin repertoirenext generation sequence (NGS)precursor B-cell

Identifiers

PMID31849931
PMCPMC6901940
OpenAlexW2991156019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.